文献速递头颈部肿瘤放疗

程序性细胞死亡蛋白-1(PD-1)抑制剂联合同步放化疗治疗复发/转移性头颈部鳞状细胞癌患者的初步协同作用分析

Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
PubMed 文献 · Radiat Oncol · 2023-07-04

本研究连续纳入2018年8月至2022年4月在四川省肿瘤医院接受PD-1抑制剂联合同步放化疗的复发/转移性头颈部鳞状细胞癌患者40例,中位随访14个月,客观缓解率70.0%、疾病控制率100%,中位无进展生存期9个月、中位总生存期19个月,3-4级不良事件总发生率65%,未观察到5级不良事件。

要点

  • 40例复发/转移性头颈部鳞癌患者接受PD-1抑制剂联合同步放化疗,客观缓解率70.0%、疾病控制率100%。
  • 中位无进展生存期9个月、中位总生存期19个月,1年与2年总生存率分别为72.8%和33.3%。
  • 3-4级不良事件总发生率65%,最常见为白细胞减少(25.0%),未观察到5级不良事件。

核心结论

  • 作者认为PD-1抑制剂联合同步放化疗作为复发/转移性头颈部鳞状细胞癌的治疗策略具有前景,毒性可接受。
  • 作者指出复发/转移性头颈部鳞状细胞癌患者治疗选择有限、预后差,免疫检查点抑制剂近期起重要作用。
  • 作者指出放化疗与免疫治疗联合在时机、放射剂量、分次等方面仍存在争议。

研究设计与样本

  • 连续纳入2018年8月至2022年4月四川省肿瘤医院接受PD-1抑制剂联合同步放化疗的复发/转移性头颈部鳞状细胞癌患者40例。
  • 所有患者接受PD-1抑制剂联合化疗,随后行PD-1抑制剂联合同步放化疗,之后行PD-1抑制剂维持治疗。
  • 采用免疫相关实体瘤疗效评价标准(irRECIST-1.1)计算客观缓解率和疾病控制率,采用常见不良事件术语标准(CTCAE-4.0)评价毒性,Kaplan-Meier法分析总生存期和无进展生存期。

主要发现

  • 中位随访时间14个月;22例仅有复发灶,16例仅有转移灶,2例同时有复发和转移灶。
  • 针对复发灶,23例患者接受中位放射剂量64 Gy(范围50-70 Gy);针对转移灶,18例患者接受中位剂量45 Gy(范围30-66 Gy)。
  • PD-1抑制剂和化疗的中位疗程数分别为8和5。
  • 治疗后客观缓解率为70.0%,疾病控制率为100%。
  • 中位总生存期19个月(范围6.3-31.7个月),1年和2年总生存率分别为72.8%和33.3%;中位无进展生存期9个月(范围3.1-14.9个月),6个月和12个月无进展生存率分别为75.5%和41.4%。

关键数值与推荐

  • 最常见的3级或4级不良事件为白细胞减少(25.0%)、中性粒细胞减少(17.5%)、贫血(10.0%)、血小板减少(5.0%)、低钠血症(2.5%)和肺炎(2.5%)。
  • 未观察到5级不良事件。
  • 3级或4级不良事件总发生率为65%。
  • 客观缓解率70.0%(95% CI 55.8%至84.2%),疾病控制率100%(95% CI 100%至100%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Programmed cell death-1 (PD-1) inhibitor was proven to be useful for the recurrent/metastatic head and neck squamous carcinoma (R/M HNSCC) patients. Though both PD-1 inhibitor alone and combination with chemotherapy showed some benefit for PFS and OS, the survival outcome was still not satisfactory. Some studies showed the possible benefit for PD-1 inhibitors combination with radiation for head and neck squamous carcinoma, however there was few studies concerned about synergy of concurrent PD-1 inhibitor combination with chemoradiotherapy for R/M HNSCC. So, we aimed to explore the potential effect and toxicity of the concurrent PD-1 inhibitor and chemoradiotherapy for R/M HNSCC. METHODS: We consecutively enrolled the R/M HNSCC patients treated with concurrent PD-1 inhibitor and chemoradiotherapy from August 2018 to April 2022 in Sichuan Cancer hospital. All the patients received the combination of PD-1 inhibitor and chemotherapy, and followed with synergy of concurrent PD-1 inhibitor and chemoradiotherapy, then maintenance PD-1 inhibitor. ORR and DCR was calculated by immune-related Response Evaluation Criteria in Solid Tumors (irRECIST-1.1), and Common terminology criteria for adverse events (CTCAE-4.0) was used to evaluate the toxicity.The Kaplan-Meier method was used to analyze OS and PFS. RESULTS: 40 R/M HNSCC patients were enrolled in our stuty. The median follow up time was 14 months. 22 patients had recurrent disease only, 16 patients had metastatic disease only, and 2 patients had both recurrence and metastasis disease. For the recurrent lesions, 23 patients received a median radiation dose of 64 Gy (range 50-70 Gy). 18 patients received a median dose of 45 Gy (range 30-66 Gy) for metastatic lesions. The median courses of PD-1 inhibitors and chemotherapy were 8 and 5 respectively. After the treatment, the ORR and DCR were 70.0% and 100%. The median OS was 19 months (range 6.3-31.7 months), with 1 and 2-years OS rates of 72.8% and 33.3%. The median PFS was 9 months (range 3.1-14.9 months), with 6 and 12 months PFS rates of 75.5% and 41.4% respectively. The PFS had no statistical significance in PD-L1 negative and positive group (7 vs 12 months, p = 0.059). The most common grade 3 or 4 adverse events(AE) were leucopenia (25.0%), neutropenia (17.5%), anemia (10.0%), thrombocytopenia (5.0%), hyponatremia (2.5%), and pneumonia(2.5%). No grade 5 AE was observed. CONCLUSIONS: The synergy of concurrent PD-1 inhibitor treatment with chemoradiotherapy shows promise as a treatment strategy and an acceptable toxicity for the R/M HNSCC patients. Recurrent/metastatic head and neck squamous carcinoma (R/M HNSCC) patients face limited treatment choices and poor prognosis. As a new treatment method, immune checkpoint inhibitor plays an important role for the R/M HNSCC patients recently. However, there were still some controversies for the combination of chemoradiotherapy and immunotherapy, such as timing, radiation dose, fractionation, and et al. In our study, the synergy of concurrent chemoradiotherapy with PD-1 inhibitor showed a promising results for the R/M HNSCC patients, with improved objective response rate (ORR) (70.0%, 95% CI 55.8% to 84.2%) and disease control rate (DCR) (100%, 95% CI 100% to 100%). The median progression-free survival (PFS) and overall survival (OS) were prolonged to 9 months (range 3.1–14.9 months) and 19 months (range 6.3–31.7 months) respectively. The toxicity was tolerable during the treatment, the total incidence rate of grade 3 or 4 adverse events were 65%, similar with other study.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Li L, Chen L, Yan L, et al. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients. Radiat Oncol. 2023. PMID: 37403098. doi:10.1186/s13014-023-02310-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。